drugset / Trial / NCT04968379
Safety, Tolerability, PK and PD of Intravenous Ferric Carboxymaltose in Infants With Iron Deficiency Anemia
Non-randomizedSingle-groupOpen-labelTreatment
Summary
An Open-Label, Multi-Center Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous Ferric Carboxymaltose (FCM) in Infants (0-1 year) with Iron Deficiency Anemia.
Timeline
- Start
- 2022-07-21
- Primary completion
- 2024-10-08
- Completion
- 2024-12-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ferric carboxymaltose | Other / unclassified | 5 mg/kg | Intravenous |
| Subject | Ferric carboxymaltose | Other / unclassified | 7.5 mg/kg | Intravenous |